Table 2.
Failure rate per country in prevalence surveys and equivalence studiesBecause of the limited number of samples tested for quality in the studies included in this review, the numbers should not be interpreted as representative of the prevalence of specific SF antidiabetics (please refer to the discussion section of the current paper for more details)
| Region/country | Prevalence survey | Equivalence study | Total | |||
| No of data points | Failure rate % (n/N) | No of data points | Failure rate % (n/N) | No of data points | Failure rate % (n/N) | |
| Africa | 2 | 4.2 (8/190) | 5 | 41.2 (14/34) | 7 | 9.8 (22/224) |
| Egypt | 1 | 9.1 (1/11) | 0 | N/A | 1 | 9.1 (1/11) |
| Libya | 0 | N/A | 1 | 0.0 (0/3) | 1 | 0.0 (0/3) |
| Nigeria | 1 | 3.9 (7/179) | 4 | 45.2 (14/31) | 5 | 10.0 (21/210) |
| Americas | 4 | 7.5 (3/40) | 1 | 0.0 (0/4) | 5 | 6.8 (3/44) |
| Argentina | 1 | 37.5 (3/8) | 0 | N/A | 1 | 37.5 (3/8) |
| Canada | 1 | 0.0 (0/17) | 0 | N/A | 1 | 0.0 (0/17) |
| Chile | 1 | 0.0 (0/11) | 0 | N/A | 1 | 0.0 (0/11) |
| Trinidad and Tobago | 0 | N/A | 1 | 0.0 (0/4) | 1 | 0.0 (0/4) |
| USA | 1 | 0.0 (0/4) | 0 | N/A | 1 | 0.0 (0/4) |
| Asia and Middle East | 12 | 12.4 (22/177) | 12 | 9.2 (7/76) | 24 | 11.5 (29/253) |
| Bangladesh | 0 | N/A | 1 | 0.0 (0/7) | 1 | 0.0 (0/7) |
| Cambodia | 2 | 18.8 (21/112)* | 0 | N/A | 2 | 18.8 (21/112) |
| CIS | 1 | 0.0 (0/2) | 0 | N/A | 1 | 0.0 (0/2) |
| India | 4 | 0.0 (0/45) | 3 | 10.3 (3/29) | 7 | 4.1 (3/74) |
| Indonesia | 1 | 25.0 (1/4) | 0 | N/A | 1 | 25.0 (1/4) |
| Iraq | 0 | N/A | 1 | 0.0 (0/5) | 1 | 0.0 (0/5) |
| Japan | 1 | 0.0 (0/4) | 0 | N/A | 1 | 0.0 (0/4) |
| Jordan | 0 | N/A | 2 | 36.4 (4/11) | 2 | 36.4 (4/11) |
| Malaysia | 0 | N/A | 1 | 0.0 (0/5) | 1 | 0.0 (0/5) |
| Pakistan | 1 | 0.0 (0/2) | 0 | N/A | 1 | 0.0 (0/2) |
| Saudi Arabia | 0 | N/A | 4 | 0.0 (0/19) | 4 | 0.0 (0/19) |
| Thailand | 1 | 0.0 (0/6) | 0 | N/A | 1 | 0.0 (0/6) |
| Turkey | 1 | 0.0 (0/2) | 0 | N/A | 1 | 0.0 (0/2) |
| Australia and Oceania | 1 | 0.0 (0/6) | 0 | N/A | 1 | 0.0 (0/6) |
| Australia | 1 | 0.0 (0/6) | 0 | N/A | 1 | 0.0 (0/6) |
| Europe | 16 | 2.7 (3/110) | 0 | N/A | 16 | 2.7 (3/110) |
| Austria | 1 | 0.0 (0/17) | 0 | N/A | 1 | 0.0 (0/17) |
| Belgium | 1 | 0.0 (0/2) | 0 | N/A | 1 | 0.0 (0/2) |
| Denmark | 1 | 0.0 (0/6) | 0 | N/A | 1 | 0.0 (0/6) |
| Finland | 1 | 0.0 (0/5) | 0 | N/A | 1 | 0.0 (0/5) |
| France | 1 | 0.0 (0/3) | 0 | N/A | 1 | 0.0 (0/3) |
| Germany | 1 | 5.9 (1/17) | 0 | N/A | 1 | 5.9 (1/17) |
| Greece | 1 | 0.0 (0/6) | 0 | N/A | 1 | 0.0 (0/6) |
| Hungary | 1 | 0.0 (0/2) | 0 | N/A | 1 | 0.0 (0/2) |
| Italy | 1 | 0.0 (0/2) | 0 | N/A | 1 | 0.0 (0/2) |
| Luxembourg | 1 | 0.0 (0/4) | 0 | N/A | 1 | 0.0 (0/4) |
| Netherlands | 1 | 0.0 (0/11) | 0 | N/A | 1 | 0.0 (0/11) |
| Portugal | 1 | 0.0 (0/4) | 0 | N/A | 1 | 0.0 (0/4) |
| Spain | 1 | 0.0 (0/6) | 0 | N/A | 1 | 0.0 (0/6) |
| Sweden | 1 | 0.0 (0/6) | 0 | N/A | 1 | 0.0 (0/6) |
| Switzerland | 1 | 0.0 (0/8) | 0 | N/A | 1 | 0.0 (0/8) |
| UK | 1 | 18.2 (2/11) | 0 | N/A | 1 | 18.2 (2/11) |
| Unstated | 1 | 0.0 (0/4) | 3 | 48.5 (16/33) | 4 | 43.2 (16/37) |
| Total | 36 | 6.8 (36/527) | 21 | 25.2 (37/147) | 57 | 10.8 (73/674) |
*In Islam 2017,39 only the number of medicine failing each quality test was mentioned. Since one medicine may fail more than one test, the failure rate was recorded as the highest possible number of samples failing one of the tests.
CIS, Commonwealth of Independent States; N/A, not applicable; SF, substandard and falsified.